Join the Bipolar Disorder group to help and get support from people like you.
Bipolar Disorder News (Page 4)
Related terms: Bipolar Affective Disorder, Bipolar Affective Mood Disorder, Bipolar I Disorder, Manic Depression, Manic Depressive Disorder, Manic Depressive Illness, Mood Disorder, Bipolar, Bipolar Depression, Ultra Rapid Cycling, Bipolar II Disorder
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena® (aripiprazole) for extended-release ...
FDA Medwatch Alert: Olanzapine: Drug Safety Communication - FDA Warns About Rare But Serious Skin Reactions
ISSUE: FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. FDA is adding a new warning to the...
FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder
September 17, 2015 – The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. “Schizophrenia and bipolar disorder c...
Actavis Receives FDA Approval of Saphris for Pediatric Patients with Bipolar I Disorder
DUBLIN, March 13, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for Saphris...
FDA Medwatch Alert: Ziprasidone (Marketed as Geodon and Generics): Drug Safety Communication - Rare But Potentially Fatal Skin Reactions
ISSUE: FDA is warning that the antipsychotic drug ziprasidone (marketed under the brand name, Geodon, and its generics) is associated with a rare but serious skin reaction that can progress to ...
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
Marlborough, Mass., June 28, 2013 – Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for the use of Latuda (lurasidone HCl) a...
FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults
MOUNTAIN VIEW, Calif., Dec. 21, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Adasuve (loxapine) Inhalation Powder 10 mg ...
Abilify (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Feb 17, 2011 - Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ – The U.S. Food and Drug Administration (FDA) today approved Zyprexa (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
gabapentin, sertraline, clonazepam, Seroquel, citalopram, escitalopram, bupropion, Lamictal, Abilify, view more... venlafaxine, lithium, lamotrigine, duloxetine, Latuda, Depakote, quetiapine, topiramate, clonidine, Vraylar, olanzapine, risperidone, Zyprexa, Risperdal, aripiprazole, Seroquel XR, Geodon, desvenlafaxine, oxcarbazepine, verapamil, levetiracetam